Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2019, Article ID 1345402, 10 pages
https://doi.org/10.1155/2019/1345402
Research Article

Combined Activation of Guanylate Cyclase and Cyclic AMP in Lung Fibroblasts as a Novel Therapeutic Concept for Lung Fibrosis

1Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Austria
2Center for Molecular Biology, University of Vienna, Austria
3Division of Respiratory Medicine, Department of Internal Medicine II, Medical University of Vienna, Austria
4Pulmonary Cell Research, Department of Biomedicine and Pneumology, Department of Internal Medicine, University Hospital and University of Basel, Switzerland

Correspondence should be addressed to Christopher Lambers; ta.ca.neiwinudem@srebmal.rehpotsirhc

Received 15 August 2018; Revised 19 December 2018; Accepted 28 January 2019; Published 7 March 2019

Academic Editor: Coline van Moorsel

Copyright © 2019 Christopher Lambers et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. L. Mora, M. Rojas, A. Pardo, and M. Selman, “Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease,” Nature Reviews Drug Discovery, vol. 16, no. 11, pp. 755–772, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. R. M. du Bois, “An earlier and more confident diagnosis of idiopathic pulmonary fibrosis,” European Respiratory Review, vol. 21, no. 124, pp. 141–146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Hutchinson, A. Fogarty, R. Hubbard, and T. McKeever, “Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review,” European Respiratory Society, vol. 46, no. 3, pp. 795–806, 2015. View at Publisher · View at Google Scholar
  4. F. Ferri, Ferri’s Clinical Advisor 2018 E-Book: 5 Books in 1, Elsevier Health Sciences, 2017.
  5. W. R. Coward, G. Saini, and G. Jenkins, “The pathogenesis of idiopathic pulmonary fibrosis,” Therapeutic Advances in Respiratory Disease, vol. 4, no. 6, pp. 367–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. L. Tatler and G. Jenkins, “TGF-beta activation and lung fibrosis,” Proceedings of the American Thoracic Society, vol. 9, no. 3, pp. 130–136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Epstein Shochet, L. Wollin, and D. Shitrit, “Fibroblast–matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype,” Respirology, vol. 23, no. 8, pp. 756–763, 2018. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Knuppel, Y. Ishikawa, M. Aichler et al., “A novel antifibrotic mechanism of nintedanib and pirfenidone inhibition of collagen fibril assembly,” American Journal of Respiratory Cell and Molecular Biology, vol. 57, no. 1, pp. 77–90, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Gabasa, P. Duch, I. Jorba et al., “Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis,” Molecular Biology of the Cell (MBoC), vol. 28, no. 26, pp. 3741–3755, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Khalil, T. V. Parekh, R. O'Connor et al., “Regulation of the effects of TGF-β1 by activation of latent TGF-β1 and differential expression of TGF-β receptors (TβR-I and TβR-II) in idiopathic pulmonary fibrosis,” Thorax, vol. 56, no. 12, pp. 907–915, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Leufgen, M. P. Bihl, J. J. Rüdiger et al., “Collagenase expression and activity is modulated by the interaction of collagen types, hypoxia, and nutrition in human lung cells,” Journal of Cellular Physiology, vol. 204, no. 1, pp. 146–154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. D. Xu, J. Hua, A. Mui, R. O'Connor, G. Grotendorst, and N. Khalil, “Release of biologically active TGF-β1 by alveolar epithelial cells results in pulmonary fibrosis,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 285, no. 3, pp. L527–L539, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. R. S. Nho and P. Hergert, “IPF fibroblasts are desensitized to type i collagen matrix-induced cell death by suppressing low autophagy via aberrant Akt/mTOR kinases,” PLoS ONE, vol. 9, no. 4, Article ID e94616, 2014. View at Google Scholar · View at Scopus
  14. I. P. Tomos, A. Tzouvelekis, V. Aidinis et al., “Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the ‘bed’ that counts and not ‘the sleepers’,” Expert Review of Respiratory Medicine, vol. 11, no. 4, pp. 299–309, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. T. E. King Jr., W. Z. Bradford, S. Castro-Bernardini et al., “A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2083–2092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Beyer, N. Reich, S. C. Schindler et al., “Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis,” Annals of the Rheumatic Diseases, vol. 71, no. 6, pp. 1019–1026, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Beyer, C. Zenzmaier, K. Palumbo-Zerr et al., “Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling,” Annals of the Rheumatic Diseases, vol. 74, no. 7, pp. 1408–1416, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. J.-P. Stasch, K. Dembowsky, E. Perzborn, E. Stahl, and M. Schramm, “Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: In vivo studies,” British Journal of Pharmacology, vol. 135, no. 2, pp. 344–355, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Deruelle, V. Balasubramaniam, A. M. Kunig, G. J. Seedorf, N. E. Markham, and S. H. Abman, “BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats,” Biology of the Neonate, vol. 90, no. 2, pp. 135–144, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Zhou, Y. Liu, M. Kahn et al., “Interactions between β-catenin and transforming growth factor-β signaling pathways mediate epithelial- mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP),” The Journal of Biological Chemistry, vol. 287, no. 10, pp. 7026–7038, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Della Latta, M. Cabiati, S. Rocchiccioli, S. Del Ry, and M.-A. Morales, “The role of the adenosinergic system in lung fibrosis,” Pharmacological Research, vol. 76, pp. 182–189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Lambers, M. Roth, P. Jaksch et al., “Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation,” Scientific Reports, vol. 8, no. 1, article no. 1087, 2018. View at Publisher · View at Google Scholar
  23. C. Lambers, L. Costa, Q. Ying et al., “Aclidinium bromide combined with formoterol inhibits remodeling parameters in lung epithelial cells through cAMP,” Pharmacological Research, vol. 102, pp. 310–318, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Lambers, Y. Qi, P. Eleni et al., “Extracellular matrix composition is modified by β2-agonists through cAMP in COPD,” Biochemical Pharmacology, vol. 91, no. 3, pp. 400–408, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Raghu, H. R. Collard, J. J. Egan et al., “An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 788–824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. N. J. Lomas, K. L. Watts, K. M. Akram, N. R. Forsyth, and M. A. Spiteri, “Idiopathic pulmonary fibrosis: Immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers,” International Journal of Clinical and Experimental Pathology, vol. 5, no. 1, pp. 58–71, 2012. View at Google Scholar · View at Scopus
  27. A. Joannes, S. Brayer, V. Besnard et al., “FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 310, no. 7, pp. L615–L629, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Pattarayan, A. Sivanantham, V. Krishnaswami et al., “Tannic acid attenuates TGF-β1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-β signaling in lung epithelial cells,” Journal of Cellular Physiology, vol. 233, no. 3, pp. 2513–2525, 2018. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Wang, Y. Liu, J. Zou, Z. Cheng, and A. Ahmad, “Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-β1 mediated Smad2/3 and ERK1/2 activation,” PLoS ONE, vol. 12, no. 9, p. e0183972, 2017. View at Publisher · View at Google Scholar
  30. H. Chen, Q. Chen, C.-M. Jiang et al., “Triptolide suppresses paraquat induced idiopathic pulmonary fibrosis by inhibiting TGFB1-dependent epithelial mesenchymal transition,” Toxicology Letters, vol. 284, pp. 1–9, 2018. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Shi, F. Li, M. Luo, J. Wei, and X. Liu, “Distinct roles of Wnt/ β-catenin signaling in the pathogenesis of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis,” Mediators of Inflammation, vol. 2017, Article ID 3520581, 16 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Song, J.-X. Zheng, J.-Z. Liu et al., “Effect of the Wnt1/β-catenin signalling pathway on human embryonic pulmonary fibroblasts,” Molecular Medicine Reports, vol. 10, no. 2, pp. 1030–1036, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Xu, W.-H. Cui, W.-C. Zhou et al., “Activation of Wnt/β-catenin signalling is required for TGF-β/Smad2/3 signalling during myofibroblast proliferation,” Journal of Cellular and Molecular Medicine, vol. 21, no. 8, pp. 1545–1554, 2017. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Song, J.-X. Zheng, J. Xu, J.-Z. Liu, L.-Y. Wu, and C. Liu, “β-catenin induces A549 alveolar epithelial cell mesenchymal transition during pulmonary fibrosis,” Molecular Medicine Reports, vol. 11, no. 4, pp. 2703–2710, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Sun, X. Gong, H. Zhu et al., “Inhibition of Wnt/β-catenin signaling promotes engraftment of mesenchymal stem cells to repair lung injury,” Journal of Cellular Physiology, vol. 229, no. 2, pp. 213–224, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Skronska-Wasek, R. Gosens, M. Königshoff, and H. A. Baarsma, “WNT receptor signalling in lung physiology and pathology,” Pharmacology & Therapeutics, vol. 187, pp. 150–166, 2018. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Shimizu, K. Dobashi, K. Iizuka et al., “Contribution of small GTPase Rho and its target protein ROCK in a murine model of lung fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 1, pp. 210–217, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. M. J. Roberts, R. E. Broome, T. C. Kent, S. J. Charlton, and E. M. Rosethorne, “The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response,” Respiratory Research, vol. 19, no. 1, article no. 2771, 2018. View at Publisher · View at Google Scholar
  39. S. Rangarajan, A. Kurundkar, D. Kurundkar et al., “Novel mechanisms for the antifibrotic action of nintedanib,” American Journal of Respiratory Cell and Molecular Biology, vol. 54, no. 1, pp. 51–59, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Conte, E. Gili, E. Fagone, M. Fruciano, M. Iemmolo, and C. Vancheri, “Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts,” European Journal of Pharmaceutical Sciences, vol. 58, no. 1, pp. 13–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Masuyama, T. Tsuruda, Y. Sekita et al., “Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart,” Hypertension Research, vol. 32, no. 7, pp. 597–603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. N. N. Mendelev, V. S. Williams, and D. A. Tulis, “Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells,” Journal of Cardiovascular Pharmacology, vol. 53, no. 2, pp. 121–131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. C. N. Joshi, D. N. Martin, J. C. Fox, N. N. Mendelev, T. A. Brown, and D. A. Tulis, “The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways,” The Journal of Pharmacology and Experimental Therapeutics, vol. 339, no. 2, pp. 394–402, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Molina-Molina, C. Machahua-Huamani, V. Vicens-Zygmunt et al., “Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells,” BMC Pulmonary Medicine, vol. 18, no. 1, p. 63, 2018. View at Google Scholar · View at Scopus
  45. E. A. Lenselink, “Role of fibronectin in normal wound healing,” International Wound Journal, vol. 12, no. 3, pp. 313–316, 2015. View at Publisher · View at Google Scholar · View at Scopus